期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 11, 期 3, 页码 725-732出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2017.03.019
关键词
Familial hypercholesterolemia; Genetic risk score; Cardiovascular disease; LDL-C; HDL-C; TG; Risk stratification; SNP
资金
- Fondation Leducq Transatlantic Networks of Excellence [13CVD03]
- Amgen Canada
BACKGROUND: Although familial hypercholesterolemia (FH) is a severe monogenic disease, it has been shown that clinical risk factors and common genetic variants can modify cardiovascular disease (CVD) risk. OBJECTIVE: The aim of the study was to evaluate the polygenic contribution to lipid traits and CVD in FH using genetic risk scores (GRSs). METHODS: Among the 20,434 subjects attending the lipid clinic, we identified and included 725 individuals who carried an FH causing mutation in this retrospective cohort study. We evaluated the association of GRSs for several traits including coronary artery disease (CAD; GRS(CAD)) as well as plasma concentrations of low-density lipoprotein cholesterol (LDL-C; GRS(LDL-C)), high-density lipoprotein cholesterol (GRS(HDL-C)) and triglycerides (GRS(TG)). RESULTS: A total of 32% (n = 231) of FH subjects presented a CVD event before their first visit. Patients in the highest GRS(LDL-C) tertile presented an LDL-C 0.4 mmol/L (15.5 mg/dL) higher than the subjects in the lowest tertile (P =.01). The GRS(CAD) was strongly associated with CVD events (odds ratio 1.80; 95% confidence interval 1.14-2.85; P =.01) even after adjustment for cardiovascular risk factors. Compared with subjects in the first tertile, those in the third GRScAD tertile had a significantly higher prevalence of events (40.9% vs 24.7%, P <.0001) and a significantly higher number of events (average 0.97 vs 0.57 [P =.0001] events per individual). CONCLUSION: These results indicate that even in the context of a severe monogenic disease such as FH, common genetic variants can significantly modify the disease phenotype. The use of the 192-SNPs GRS(CAD) may refine CVD risk prediction in FH patients and this could lead to a more personalized approach to therapy. (C) 2017 National Lipid Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据